T0078

Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.

Lapatinib ditosylate (Lapatinib tosilate) monohydrate is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib ditosylate monohydrate therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury.

L-Histidinol-d3 ((S)-2-Amino-3-(1H-imidazol-5-yl)propan-1-ol-d3) is a deuterium-labeled form of L-Histidinol, which acts as an oral inhibitor of histidyl-tRNA synthetase. It disrupts the initial phase of protein synthesis, thereby affecting cell proliferation and metabolism. Additionally, L-Histidinol regulates the sensitivity of tumor cells to chemotherapeutic agents, potentially reducing the toxicity to normal tissues while enhancing the responsiveness of tumor cells to these agents.

Lapatinib-D4 is a deuterated compound of Lapatinib. Lapatinib (T0078) has a CAS number of 231277-92-2. Lapatinib (T0078) is a dual inhibitor of Lapatinib (T0078) is a dual ErbB2/EGFR (IC50: 9.2/10.8 nM) inhibitor